Charles River Laboratories International (NYSE:CRL) Coverage Initiated at TD Cowen

Stock analysts at TD Cowen assumed coverage on shares of Charles River Laboratories International (NYSE:CRL) in a note issued to investors on Wednesday, Briefing.com reports. The firm set a “market perform” rating and a $212.00 price target on the medical research company’s stock. TD Cowen’s price target points to a potential upside of 7.63% from the company’s current price.

CRL has been the topic of a number of other research reports. JPMorgan Chase & Co. raised their target price on shares of Charles River Laboratories International from $225.00 to $250.00 and gave the stock an “overweight” rating in a report on Thursday, August 10th. StockNews.com upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating in a research note on Sunday. Citigroup cut Charles River Laboratories International from a “buy” rating to a “neutral” rating and cut their price target for the company from $260.00 to $225.00 in a report on Monday, July 10th. Finally, Bank of America increased their price objective on Charles River Laboratories International from $235.00 to $245.00 and gave the stock a “buy” rating in a report on Thursday, August 10th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $244.55.

Charles River Laboratories International Trading Down 1.3 %

Shares of CRL opened at $196.98 on Wednesday. Charles River Laboratories International has a one year low of $181.22 and a one year high of $262.00. The stock has a 50-day moving average price of $206.21 and a 200 day moving average price of $202.96. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.21 and a current ratio of 1.49. The company has a market capitalization of $10.10 billion, a P/E ratio of 20.89, a P/E/G ratio of 1.83 and a beta of 1.33.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, August 9th. The medical research company reported $2.69 EPS for the quarter, beating analysts’ consensus estimates of $2.63 by $0.06. Charles River Laboratories International had a net margin of 11.58% and a return on equity of 18.99%. The firm had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.05 billion. During the same period in the prior year, the firm posted $2.77 EPS. The firm’s revenue was up 8.9% compared to the same quarter last year. Sell-side analysts forecast that Charles River Laboratories International will post 10.48 EPS for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 700 shares of the company’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $216.52, for a total value of $151,564.00. Following the transaction, the executive vice president now directly owns 24,983 shares of the company’s stock, valued at $5,409,319.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Charles River Laboratories International news, VP William D. Barbo sold 5,763 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $217.24, for a total value of $1,251,954.12. Following the completion of the sale, the vice president now directly owns 3,592 shares of the company’s stock, valued at $780,326.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Joseph W. Laplume sold 700 shares of the firm’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $216.52, for a total transaction of $151,564.00. Following the transaction, the executive vice president now owns 24,983 shares in the company, valued at approximately $5,409,319.16. The disclosure for this sale can be found here. Insiders sold 7,934 shares of company stock valued at $1,722,048 in the last quarter. Company insiders own 1.30% of the company’s stock.

Hedge Funds Weigh In On Charles River Laboratories International

Several hedge funds have recently bought and sold shares of CRL. Mitsubishi UFJ Trust & Banking Corp increased its holdings in shares of Charles River Laboratories International by 0.3% during the 1st quarter. Mitsubishi UFJ Trust & Banking Corp now owns 158,988 shares of the medical research company’s stock valued at $32,087,000 after acquiring an additional 512 shares during the last quarter. CIBC Asset Management Inc raised its position in shares of Charles River Laboratories International by 6.1% in the fourth quarter. CIBC Asset Management Inc now owns 7,127 shares of the medical research company’s stock valued at $1,553,000 after purchasing an additional 412 shares during the period. Deutsche Bank AG lifted its stake in shares of Charles River Laboratories International by 1.7% in the fourth quarter. Deutsche Bank AG now owns 188,646 shares of the medical research company’s stock worth $41,106,000 after buying an additional 3,223 shares during the last quarter. Congress Wealth Management LLC DE boosted its holdings in shares of Charles River Laboratories International by 4.6% during the 1st quarter. Congress Wealth Management LLC DE now owns 53,330 shares of the medical research company’s stock worth $10,763,000 after buying an additional 2,358 shares during the period. Finally, Asset Management One Co. Ltd. grew its stake in Charles River Laboratories International by 6.6% in the 1st quarter. Asset Management One Co. Ltd. now owns 20,782 shares of the medical research company’s stock valued at $4,194,000 after buying an additional 1,278 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).